In the last three months, 9 analysts have published ratings on Illumina (NASDAQ:ILMN), offering a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $168.11, along with a high estimate of $258.00 and a low estimate of $100.00. This current average represents a 13.79% decrease from the previous average price target of $195.00.

Breaking Down Analyst Ratings: A Detailed Examination

The standing of Illumina among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

To gain a panoramic view of Illumina's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Illumina analyst ratings.

All You Need to Know About Illumina

Illumina's Economic Impact: An Analysis

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Illumina displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 0.36%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -67.38%, the company may need to address challenges in effective cost control.

Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -12.11%, the company may need to address challenges in generating satisfactory returns for shareholders.

Return on Assets (ROA): Illumina's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -6.89%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Illumina's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.39.

The Basics of Analyst Ratings

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.